Angiogenesis 2023: Ellipsoid zone integrity in dry AMD
February 10th 2023Angiogenesis
In a presentation at the Angiogenesis, Exudation, and Degeneration 2023 conference, Justis Ehlers, MD, presented "Ellipsoid Zone Integrity in Dry AMD: An Imaging Biomarker for Progression Risk and Clinical Trial Endpoint.”
Angiogenesis 2023: Comparing GA phenotypes and progression rates in Asians, non-Asians
February 10th 2023Angiogenesis
A study conducted by Gemmy Cheung, MBBS, FRCOphth and colleagues shows geographic atrophy (GA) lesion phenotypes, associated features, and growth rates differ between Asians and non-Asians.
Poll: Will you be attending the 2023 virtual Angiogenesis, Exudation, and Degeneration meeting?
February 1st 2023Angiogenesis
A poll for retina specialists: Let us know if you will be logging on for this annual Bascom Palmer Eye Institute symposium, which will be held virtually on February 10 and 11, 2023.
Risk of rhegmatogenous retinal detachment rises following cataract surgery
October 4th 2022AAO
The investigators undertook a study to determine the incidence of rhegmatogenous retinal detachments 1 year after cataract using the IRIS Registry data and to determine the demographic features, ocular comorbidities, and intraoperative factors associated with an increased risk of detachment development.
Late-breaking: Janssen announces data from 2 gene therapy programs
October 2nd 2022AAO
Janssen noted that results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa.
Faricimab eradicates center-involved DME faster than aflibercept
October 2nd 2022AAO
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
Continuous range-of-motion IOL scores high in patient satisfaction
September 30th 2022AAO
Investigators reported that the safety and efficacy of the Tecnis Synergy IOL model ZFR00V indicates that it may be a good option for patients who desire meaningful gains in uncorrected visual acuity at all distances.
OCS-01 improves macular thickness, visual acuity in patients with DME, according to Phase 2 data
September 7th 2022EURETINA
According to a presentation by Oculis at EURETINA, the dataset shows that OCS-01 eye drops were more effective than vehicle in reducing central macular thickness and improving visual acuity in patients with DME as per the pre-defined criteria for statistical superiority in the study protocol.
LIGHT study: First analysis of gene therapy for RPE65 inherited retinal dystrophies
September 3rd 2022EURETINA
At the 1-month evaluation, the full-field stimulus threshold had median decrease of -33.2 decibels (dB) (-33.7; -19.8) dB, which remained stable until the last assessment. Visual fields and visual acuity did not change significantly.